The second edition of “The supply of plasma-derived medicinal products in the future of Europe” was held 23 and 24 April in Rome, at the Hotel Ripa. The event, dedicated to all professionals in the sector, involved the main players in the blood system and the plasma-derived sector, both at a national and international level.

The main objective of the meeting was to share the different experiences on all the main topics relating to plasma derivation. A particular in-depth study was then dedicated to the topic of the new European regulation on Substances of human origin (SOHO), which was voted by the European Parliament on 24 April.

Venue:
Hotel Ripa, via degli Orti di Trastevere, 3, Roma

For info:
The programme

Presentations
Session 1:
1. P. Robert – The global demand for PDMPs: Current scenario and future trends
2. F. Candura – The Italian experience on PDMPs contingency
3. J. Pink – Austrialian experience on PDMPs contingency
4. S. Grenier – Plasma derived products demand: a Canadian perspective
5. T. Iijima – An overview of the Japanese blood services and events affecting the supply of PDMPs in Japan
6. F. Moftah – Current situation of the plasma fractionation in the African continent
7. L. Larrea – Country experiences on PDMPs contingency: Spain
8. S. Akuličs – Experience of Latvia on contingency of PDMPs

Session 2:
1. P. O’Leary – SUPPLY Project in a nutshell
2. A. de Fijter – SUPPLY Work package 3: Plasma collection and processing best practises
3. V. De Angelis – Recommendations on plasma collection and PDMPs management
4. S. L. Sasongko – Recommendations on appropriate and prioritised use of IG
5. M. A. Vesga Carasa – Position paper on distribution PDMPs coming from EU/national plasma

Roundtable:
1. J.B. Thibert – Donors and patients regarding plasma supply: Ethical implications
2. M. Clement – Donor retention and recruitment strategies
3. K. van den Hurk – Donor protection
4. S. L. Sasongko – Patient protection linked to SUPPLY WP6 Recommendations

Session 3:
1. D. Di Giorgio – CHESSMEN: “Coordination and Harmonisation of Existing Systems against Shortages of Medicines – European Network”
2. L. Marrero Ortiz – Identification of the root causes of observed medicines shortages
3. M. Tovornik – CHESSMEN: Identification of best practices to address medicines shortages
4. G. Eibenstein – Digital information exchange for monitoring and reporting medicines shortages
5. J. Linnolahti – Reducing the likelihood of medicines shortages via preventive and mitigation strategies
6. K. Kruttwig – Monitoring and mitigating shortages of medicines and management of public health emergencies/major events
7. M. Hotchko – Asia PDMPs usage and trends
8. L. von Bonsdorff – Insights on PDMPs availability
9. M. Van Baelen – Access to plasma-derived medicines

Open discussion:
1. A. Farrugia – Open discussion “Availability of PDMPs and timely access to therapies”: Musings of the moderator

Session 4:
1. S. Van der Spiegel – New SoHO regulation and plasma supply
2. A. Rodiadis – The EU pharmaceutical reform
3. R. Forde – EU SoHO regulation: EDQM perspectives
4. M. J. van der Werf – An overview of the new and upcoming EU legislation on substances of human origin and pharmaceuticals: Perspectives and implications
5. K. Kruttwig – Proposed reform of the pharmaceutical legislation